WO2003088973A1 - Combination of brimonidine and timolol for topical ophthalmic use - Google Patents

Combination of brimonidine and timolol for topical ophthalmic use Download PDF

Info

Publication number
WO2003088973A1
WO2003088973A1 PCT/US2003/010885 US0310885W WO03088973A1 WO 2003088973 A1 WO2003088973 A1 WO 2003088973A1 US 0310885 W US0310885 W US 0310885W WO 03088973 A1 WO03088973 A1 WO 03088973A1
Authority
WO
WIPO (PCT)
Prior art keywords
timolol
effective amount
brimonidine
composition according
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/010885
Other languages
English (en)
French (fr)
Inventor
Chin-Ming Chang
Gary J. Beck
Cynthia C. Pratt
Amy L. Batoosingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003088973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES03726234T priority Critical patent/ES2399045T3/es
Priority to JP2003585725A priority patent/JP2005523316A/ja
Priority to EC2003004742A priority patent/ECSP034742A/es
Priority to SI200332241T priority patent/SI1496912T1/sl
Priority to MXPA03008401A priority patent/MXPA03008401A/es
Priority to CA002440764A priority patent/CA2440764C/en
Priority to EP03726234.2A priority patent/EP1496912B9/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to AU2003228480A priority patent/AU2003228480C1/en
Priority to HK05100007.6A priority patent/HK1067549B/xx
Priority to KR1020037015881A priority patent/KR100723189B1/ko
Priority to DK03726234.2T priority patent/DK1496912T3/da
Priority to BR0302584-5A priority patent/BR0302584A/pt
Priority to MX2014003586A priority patent/MX368377B/es
Publication of WO2003088973A1 publication Critical patent/WO2003088973A1/en
Priority to NO20044450A priority patent/NO326579B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/001—Arrangement of electric circuit elements in or on lighting devices the elements being electrical wires or cables
    • F21V23/002—Arrangements of cables or conductors inside a lighting device, e.g. means for guiding along parts of the housing or in a pivoting arm
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/003—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array
    • F21V23/004—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array arranged on a substrate, e.g. a printed circuit board
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/02—Arrangement of electric circuit elements in or on lighting devices the elements being transformers, impedances or power supply units, e.g. a transformer with a rectifier
    • F21V23/023—Power supplies in a casing
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0066—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form characterised by the light source being coupled to the light guide
    • G02B6/0073—Light emitting diode [LED]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • This invention relates to the topical ophthalmic use of brimonidine in combination with timolol when indicated for treatment of glaucoma or ocular hypertension.
  • Such combinations or formulations are available for separate use in the ophthalmic art and have been combined in serial application during the course of treatment of glaucoma.
  • problems and expressed reservations in the ophthalmic community about patient compliance when the patient is required to administer separate medications to treat a single disease or condition such as glaucoma.
  • an effective and safe topical ophthalmic pharmaceutical composition including brimonidine and timolol which has increased stability and requires a lower effective concentration of preservative as compared to the individual agents taken alone.
  • Brimonidine is disclosed in U.S. Patent 3,890,319.
  • the use of brimonidine for providing neuroprotection to the eye is disclosed in U.S. Patents 5,856,329; 6,194,415 and 6,248,741.
  • Brimonidine is an alpha adrenergic agonist represented by the following formula:
  • brimonidine 5-Bromo-6-(2- imidazolidinylideneamino)quinoxaline L-tartrate.
  • Timolol is a beta adrenergic agent represented by the following formula:
  • Brimonidine is available from Allergan, Inc., Irvine, California as an ophthalmic pharmaceutical product having the name Alphagan®. Timolol is available from various sources, including Merck Co., Rahway, New Jersey.
  • compositions of the present invention are administered topically.
  • the dosage is 0.001 to 1.0, e.g. mg/per eye BID; wherein the cited mass figures represent the sum of the two components, brimonidine and timolol.
  • the compositions of the present invention can be administered as solutions in a suitable ophthalmic vehicle.
  • compositions for topical admimstration are preferably formulated as 0.01 to 0.5 percent by weight brimonidine and 0.1 to 1.0 percent by weight timolol solution in water at a pH of 4.5 to 8.0, e.g. about 6.9. While the precise regimen is left to the discretion of the clinician, it is recommended that the solution be topically applied by placing one drop in each eye two times a day.
  • Other ingredients which may be desirable to use in the ophthalmic preparations of the present invention include preservatives, co-solvents and viscosity building agents.
  • Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. In the prior art ophthalmic products, typically such preservatives are employed at a level of from 0.004% to 0.02%. In the compositions of the present application the preservative, preferably benzalkonium chloride, may be employed at a level of from 0.001% to less than 0.01%, e.g.
  • a concentration of benzalkonium chloride of 0.005% is sufficient to preserve the compositions of the present invention from microbial attack. This concentration may be advantageously compared to the requirement of 0.01% 5 benzalkonium chloride to preserve timolol in the individual, commercially-available ophthalmic products. Moreover, it has been found that adequate lowering of intraocular pressure has been obtained when administering the compositions of this invention twice a day as compared to the FDA-approved regimen wherein brimonidine ophthalmic solution, i.e.
  • Alphagan® ophthalmic 0 solution is administered three times a day and timolol ophthalmic solution, i.e. Timoptic® ophthalmic solution is administered twice a day.
  • Timoptic® ophthalmic solution is administered twice a day.
  • FDA-approved adjunctive therapy wherein s Alphagan® and Timoptic® are serially administered, the patient is exposed to almost three times the concentration of benzalkonium chloride as compared to the administration of the compositions of this invention twice a day.
  • benzalkonium chloride at high concentrations is cytotoxic. Therefore, minimizing the patient's exposure to benzalkonium chloride, while o providing the preservative effects afforded by benzalkonium chloride, is clearly desirable.
  • compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition.
  • cosolvents include polysorbate 20, 60, and 80, Pluronic F68, F-84 and P-103, cyclodextrin, or other agents known to those skilled in the art.
  • co-solvents are employed at a level of from 0.01 % to 2% by weight.
  • Viscosity increased above that of simple aqueous solutions maybe desirable to increase ocular absorption of the active compound, to decrease variability in dispensing the formulation, to decrease physical separation of components of a suspension or emulsion of the formulation and/or to otherwise improve the ophthalmic formulation.
  • Such viscosity building agents include as examples polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
  • the present invention further comprises an article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for lowering intraocular pressure and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for lowering intraocular pressure and wherein said pharmaceutical agent comprises an effective amount of brimonidine and an effective amount of timolol.
  • packaging material comprises a label which indicates the pharmaceutical agent can be used for lowering intraocular pressure
  • said pharmaceutical agent comprises an effective amount of brimonidine and an effective amount of timolol.
  • the following example is a representative pharmaceutical composition of the invention for topical use when indicated for treating glaucoma.
  • EXAMPLE I The combination of active pharmaceutical ingredients is as follows: Brimonidine Tartrate 0.20 %(w/v) and Timolol Maleate 0.68 %(w/v) (Equivalent to 0.50 %(w/v) timolol)
  • the Brimonidine-Timolol combination formulation presented in the Table, below, is a sterile, preserved, aqueous solution.
  • the formulation vehicle is based upon a timolol ophthalmic solution which contains an isotonic phosphate buffer system at pH 6.9.
  • the formulation preservative is benzalalkonium chloride (BAK) at a concentration of 0.005 %(w/v) (50 ppm).
  • BAK benzalalkonium chloride
  • the formulation passes regulatory required preservative efficacy testing (PET) criteria for USP (United States Pharmacopoeia) and EP (European Pharmacopoeia-A and -B over 24 months.
  • Example I The pharmaceutical composition of Example I is used in the clinical study reported below.
  • Randomization patients were randomized to one of the 3 masked treatment groups (Combination, Brimonidine or Timolol) based on an even allocation at each site Visit Schedule: prestudy, baseline (day 0), week 2, week 6, month 3, month 6, month 9, and month 12
  • Diagnosis ocular hypertension, chronic open-angle glaucoma, chronic angle- closure glaucoma with patent iridotomy, pseudoexfoliative glaucoma or pigmentary glaucoma and requiring bilateral treatment.
  • Key Inclusion Criteria > 18 years, day 0 (post-washout) intraocular pressure (IOP) > 22 mm Hg and ⁇ 34 mm Hg in each eye and asymmetry of IOP ⁇ 5 mm Hg, best- corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity equivalent to a Snellen score of 20/100 or better in each eye.
  • IOP intraocular pressure
  • EDRS Early Treatment of Diabetic Retinopathy Study
  • Active control ALPHAGAN ® (brimonidine tartrate ophthalmic solution) 0.2%, one drop ( ⁇ 35 ⁇ L) instilled in each eye TDD in the morning, afternoon, and evening.
  • Active control timolol ophthalmic solution 0.5% one drop (-35 ⁇ L) instilled in each eye BID in the morning and evening; and vehicle of the Combination ophthalmic solution, one drop ( ⁇ 35 ⁇ L) instilled in each eye once daily (QD) in the afternoon (for masking purposes).
  • IOP hours 0, 2, 7, and 9
  • patient satisfaction questionnaire patient comfort of study medication questionnaire
  • AE Adverse events
  • biomicroscopy biomicroscopy
  • visual acuity VA
  • visual field ophthalmoscopy
  • cup/disc ratio heart rate
  • blood pressure blood pressure
  • hematology serum chemistry
  • urinalysis urinalysis and pregnancy test.
  • Safety analyses included all patients who received at least 1 dose of study medication. Analyses were performed for the primary efficacy variable IOP using the intent-to-treat (ITT) population with last observation carried forward (LOCF), and the per protocol population with observed cases.
  • ITT intent-to-treat
  • LOCF last observation carried forward
  • a 2-way A ⁇ ONA model with factors for treatment and investigator was used for the analysis of IOP. Comparisons were made between the Combination and each of the 2 monotherapies in a pairwise fashion using contrasts from the A ⁇ ONA model, with the same error term. A separate A ⁇ ONA model was employed at each hour/visit measurement of IOP. Each of the 2 null hypotheses (Combination versus Timolol and Combination versus Brimonidine) was tested at the 0.05 significance level. Point estimates of the mean treatment differences, as well as 2-sided 95% confidence intervals (CI) of the difference, were provided at each timepoint.
  • CI 2-sided 95% confidence intervals
  • the mean decrease from baseline diurnal IOP was statistically significantly greater with Combination than with Brimonidine at hours 0, 2, and 7 at all follow-up visits 5 (p ⁇ 0.001).
  • clinically significant differences of more than 1.5 mm Hg in mean change from baseline IOP favoring Combination over Brimonidine were seen at hours 0, 2, and 7 at all follow-up visits.
  • the decreases from baseline diurnal IOP were greater for the Combination group than the Brimonidine group at all follow-up visits, although the differences were not statistically l o significant (p > 0.104).
  • mean ⁇ standard deviation (SD) plasma brimonidine concentrations 1 hour postdose at week 2 and month 3 were 49.7 ⁇ 36.1 and 52.8 ⁇ 46.7 pg/mL, respectively.
  • mean ⁇ SD plasma brimonidine concentrations at week 2 and month 3 were 81.0 ⁇ 63.8 and 78.6 ⁇ 48.9 pg/mL, respectively.
  • mean + SD plasma timolol concentrations at week 2 and month 3 were 0.499 ⁇ 0.327 and 0.586 ⁇ 0.580 ng/mL, respectively.
  • mean ⁇ SD plasma timolol 5 concentrations at week 2 and month 3 were 0.950 ⁇ 0.709 and 0.873 ⁇ 0.516 ng/mL, respectively.
  • Plasma brimonidine and timolol concentrations 1 hour postdose were steady and did not increase over the 3-month study duration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Power Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
PCT/US2003/010885 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use Ceased WO2003088973A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2014003586A MX368377B (es) 2002-04-19 2003-04-09 Combinacion de brimonidina y timolol para uso oftalmico, topico.
AU2003228480A AU2003228480C1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use
EC2003004742A ECSP034742A (es) 2003-04-09 2003-04-09 Combinacion de brimonidina y timolol para uso oftalmologico topico
SI200332241T SI1496912T1 (sl) 2002-04-19 2003-04-09 Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo
MXPA03008401A MXPA03008401A (es) 2002-04-19 2003-04-09 Combinacion de brimonidina y timolol para uso oftalmico, topico.
CA002440764A CA2440764C (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use
EP03726234.2A EP1496912B9 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use
ES03726234T ES2399045T3 (es) 2002-04-19 2003-04-09 Combinación de brimonidina y timolol para uso oftálmico tópico
HK05100007.6A HK1067549B (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use
KR1020037015881A KR100723189B1 (ko) 2002-04-19 2003-04-09 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
JP2003585725A JP2005523316A (ja) 2002-04-19 2003-04-09 眼科局所用のブリモニジンとチモロールとの組み合わせ
DK03726234.2T DK1496912T3 (da) 2002-04-19 2003-04-09 Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse
BR0302584-5A BR0302584A (pt) 2002-04-19 2003-04-09 Combinação de brimonidina e timolol para uso oftálmico tópico
NO20044450A NO326579B1 (no) 2002-04-19 2004-10-19 Oftalmisk farmasoytisk preparat inneholdende brimonidin og timolol samt anvendelse av dette for fremstilling av medikament for behandling av oyet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/126,790 2002-04-19
US10/126,790 US7030149B2 (en) 2002-04-19 2002-04-19 Combination of brimonidine timolol for topical ophthalmic use

Publications (1)

Publication Number Publication Date
WO2003088973A1 true WO2003088973A1 (en) 2003-10-30

Family

ID=29215107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010885 Ceased WO2003088973A1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use

Country Status (17)

Country Link
US (16) US7030149B2 (https=)
EP (2) EP2241319A1 (https=)
JP (1) JP2005523316A (https=)
KR (1) KR100723189B1 (https=)
CN (2) CN101664414A (https=)
BR (1) BR0302584A (https=)
CA (1) CA2440764C (https=)
CY (1) CY1114048T1 (https=)
DK (1) DK1496912T3 (https=)
ES (1) ES2399045T3 (https=)
MX (2) MXPA03008401A (https=)
NO (1) NO326579B1 (https=)
NZ (1) NZ528945A (https=)
PT (1) PT1496912E (https=)
SI (1) SI1496912T1 (https=)
TW (1) TWI351959B (https=)
WO (1) WO2003088973A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050615A1 (en) * 2005-10-25 2007-05-03 Allergan, Inc. Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension
WO2007121077A1 (en) * 2006-04-10 2007-10-25 Allergan, Inc. Brimonidine and timolol compositions
JP2008511628A (ja) * 2004-08-27 2008-04-17 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
WO2011087790A1 (en) * 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
US8748425B2 (en) 2002-04-19 2014-06-10 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
WO2016149498A1 (en) * 2015-03-19 2016-09-22 Allergan, Inc. Fixed dose combination of bromonidine and timolol
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
AU2016216627B2 (en) * 2011-11-10 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2018144742A1 (en) * 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
EP2598119B1 (en) 2010-07-29 2018-09-19 Allergan, Inc. Preservative free brimonidine and timolol solutions
US10201535B2 (en) 2011-11-10 2019-02-12 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US12599607B2 (en) 2018-03-28 2026-04-14 Novaliq Gmbh Pharmaceutical compositions comprising timolol

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
US20080051406A1 (en) * 2006-08-25 2008-02-28 Richard Graham Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100028266A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
JP5218167B2 (ja) 2009-03-11 2013-06-26 日立電線株式会社 コネクタ
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8317973B2 (en) 2009-11-11 2012-11-27 Kemira Chemical, Inc. Polyester surfactants for deinking
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
RS67824B1 (sr) * 2017-06-08 2026-03-31 Eye Therapies Llc Oftalmološke kompozicije koje sadrže brimonidin i ketotifen za upotrebu u lečenju alergija
US20200108064A1 (en) * 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
CN111132640B (zh) * 2017-09-25 2023-01-10 佛罗里达大学研究基金会股份有限公司 从含亲水药物的滴眼剂中除去防腐剂
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
US11871308B2 (en) * 2019-07-29 2024-01-09 TapText llc System and method for link-initiated dynamic-mode communications
EP4057941A4 (en) 2019-11-15 2024-05-29 Silk Technologies Ltd. Stable formulations of silk-derived protein
MX2022007389A (es) 2019-12-19 2022-08-10 Tearclear Corp Remocion del conservante de las gotas para los ojos.
CN120617269A (zh) * 2025-06-16 2025-09-12 鲁南贝特制药有限公司 一种溴莫尼定噻吗洛尔滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4195085A (en) 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE4201079C3 (de) 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
SK77396A3 (en) 1993-12-17 1997-01-08 Procter & Gamble 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5564596A (en) * 1994-05-05 1996-10-15 Allergan, Inc. Multiple fluid dispensing device for low surface tension formulations
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
EP1069913B1 (en) * 1998-04-07 2003-07-23 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
WO2002005848A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
TWI292914B (https=) * 2002-01-17 2008-01-21 Macronix Int Co Ltd
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
KR100521364B1 (ko) * 2002-11-18 2005-10-12 삼성전자주식회사 플레쉬 메모리 셀들의 프로그램 오판을 방지하고 균일한문턱 전압 산포를 가질 수 있는 플레쉬 메모리 장치 및 그프로그램 검증 방법

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HOMMER, A. B. ET AL.: "efficacy and safety of unoprostone, dorzolamide, and brimonidine in adjunctive therapy to timolol in patients with primary open-angle glaucoma and ocular hypertension", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 42, no. 4, supp., 15 March 2001 (2001-03-15), pages 554, XP009014420 *
HOYNG, P. F.J. AND VAN BEEK, L.M.: "Pharmacological therapy of glaucoma", DRUGS, vol. 59, no. 3, March 2000 (2000-03-01), pages 411 - 434, XP009014419 *
LARSSON, L.: "Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination", ARCH OPHTHALMOL, vol. 119, - April 2001 (2001-04-01), pages 492 - 495, XP009014425 *
SCHUMAN, J.S.: "Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension", SURVEY OF OPHTHALMOLOGY, vol. 41, no. 1, - November 1996 (1996-11-01), pages s27 - s37, XP009014391 *
STEWART W C: "PERSPECTIVES IN THE MEDICAL TREATMENT OF GLAUCOMA", CURRENT OPINION IN OPHTHALMOLOGY, PHILADELPHIA, PA, US, vol. 10, no. 2, April 1999 (1999-04-01), pages 99 - 108, XP000914581, ISSN: 1040-8738 *
WANG, R. ET AL.: "Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes", JOURNAL OF GLAUCOMA, vol. 9, - 2000, pages 458 - 462, XP009014399 *
YÜKSEL, N. ET AL.: "The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma", OPHTHALMOLOGICA, vol. 213, - 1999, pages 228 - 233, XP009014398 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770453B2 (en) 2002-04-19 2017-09-26 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
US8748425B2 (en) 2002-04-19 2014-06-10 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
US9907801B1 (en) 2002-04-19 2018-03-06 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
US9474751B1 (en) 2002-04-19 2016-10-25 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
US9907802B1 (en) 2002-04-19 2018-03-06 Allergan Sales, Llc Combination of brimonidine and timolol for topical ophthalmic use
JP2008511628A (ja) * 2004-08-27 2008-04-17 アラーガン、インコーポレイテッド α−２−アドレナリンアゴニスト成分を含有する組成物
JP2012246304A (ja) * 2004-08-27 2012-12-13 Allergan Inc α−２−アドレナリンアゴニスト成分を含有する組成物
US7534795B2 (en) 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US7960382B2 (en) 2005-10-25 2011-06-14 Allergan, Inc. Compounds and their use related to compositions for treating disease
WO2007050615A1 (en) * 2005-10-25 2007-05-03 Allergan, Inc. Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension
WO2007121077A1 (en) * 2006-04-10 2007-10-25 Allergan, Inc. Brimonidine and timolol compositions
WO2011087790A1 (en) * 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
US9801891B2 (en) 2009-12-22 2017-10-31 Allergan, Inc. Compositions and methods for lowering intraocular pressure
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2598119B1 (en) 2010-07-29 2018-09-19 Allergan, Inc. Preservative free brimonidine and timolol solutions
US10792288B2 (en) 2010-07-29 2020-10-06 Allergan, Inc. Preservative free brimonidine and timolol solutions
AU2016216627B2 (en) * 2011-11-10 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US10201535B2 (en) 2011-11-10 2019-02-12 Allergan, Inc. Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN107427460A (zh) * 2015-03-19 2017-12-01 阿勒根公司 溴莫尼定和噻吗洛尔的固定剂量组合
WO2016149498A1 (en) * 2015-03-19 2016-09-22 Allergan, Inc. Fixed dose combination of bromonidine and timolol
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
WO2018144742A1 (en) * 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
US12599607B2 (en) 2018-03-28 2026-04-14 Novaliq Gmbh Pharmaceutical compositions comprising timolol

Also Published As

Publication number Publication date
US20040102445A1 (en) 2004-05-27
EP1496912A1 (en) 2005-01-19
US8354409B2 (en) 2013-01-15
CY1114048T1 (el) 2016-07-27
KR100723189B1 (ko) 2007-05-29
US8748425B2 (en) 2014-06-10
US20180064720A1 (en) 2018-03-08
CA2440764C (en) 2005-10-25
ES2399045T3 (es) 2013-03-25
PT1496912E (pt) 2013-02-13
US9474751B1 (en) 2016-10-25
CN1516588A (zh) 2004-07-28
US7030149B2 (en) 2006-04-18
CA2440764A1 (en) 2003-10-19
US8133890B2 (en) 2012-03-13
NO326579B1 (no) 2009-01-12
NZ528945A (en) 2006-04-28
US20200129520A1 (en) 2020-04-30
US20130116255A1 (en) 2013-05-09
CN100558364C (zh) 2009-11-11
BR0302584A (pt) 2004-03-09
US9770453B2 (en) 2017-09-26
AU2003228480A1 (en) 2003-11-03
EP1496912B1 (en) 2013-01-09
JP2005523316A (ja) 2005-08-04
TWI351959B (en) 2011-11-11
SI1496912T1 (sl) 2013-03-29
US7323463B2 (en) 2008-01-29
TW200402296A (en) 2004-02-16
MX368377B (es) 2019-09-30
MXPA03008401A (es) 2004-03-16
NO20044450L (no) 2004-11-09
US9907802B1 (en) 2018-03-06
HK1067549A1 (zh) 2005-06-03
CN101664414A (zh) 2010-03-10
US20170157138A1 (en) 2017-06-08
US7320976B2 (en) 2008-01-22
EP1496912B9 (en) 2015-06-17
US20210405280A1 (en) 2021-12-30
US20030199509A1 (en) 2003-10-23
US20120184551A1 (en) 2012-07-19
US20130196995A1 (en) 2013-08-01
US20180064721A1 (en) 2018-03-08
EP2241319A1 (en) 2010-10-20
US20160303119A1 (en) 2016-10-20
US20130324534A1 (en) 2013-12-05
US20180042932A1 (en) 2018-02-15
KR20040100844A (ko) 2004-12-02
US9907801B1 (en) 2018-03-06
US20150087647A1 (en) 2015-03-26
AU2003228480B2 (en) 2006-07-27
US20080132512A1 (en) 2008-06-05
DK1496912T3 (da) 2013-04-02
US20030199507A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US9907801B1 (en) Combination of brimonidine and timolol for topical ophthalmic use
US7642258B2 (en) Combination of brimonidine and timolol for topical ophthalmic use
AU2003228480C1 (en) Combination of brimonidine and timolol for topical ophthalmic use
AU2007254671B2 (en) Combination of brimonidine and timolol for topical ophthalmic use
AU2006225278B2 (en) Combination of brimonidine and timolol for topical ophthalmic use
HK1067549B (en) Combination of brimonidine and timolol for topical ophthalmic use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2440764

Country of ref document: CA

Ref document number: 03072653

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008401

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1312/KOLNP/2003

Country of ref document: IN

Ref document number: 01312/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 528945

Country of ref document: NZ

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003726234

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003228480

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020037015881

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 038004682

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003585725

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2003726234

Country of ref document: EP